Alimentary Pharmacology & Therapeutics

Papers
(The H4-Index of Alimentary Pharmacology & Therapeutics is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
156
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC154
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease154
AP&T: Editors' Declarations of Interest120
Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials93
87
Issue Information76
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep75
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis70
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis66
Issue Information65
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation64
64
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease62
Editorial: The future of managing drug induced liver injury61
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC60
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted59
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?59
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply58
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply58
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply58
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B58
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough55
Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability o54
Editorial: Plants against animals52
Editorial: biomarkers for alcohol‐related liver fibrosis—almost there?52
Editorial: risk of pneumonia in IBD—reading between the lines!51
Letter: is wireless oesophageal pH monitoring the best technique to evaluate night‐time reflux?51
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease50
Letter: Ozanimod and latent tuberculosis49
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply47
Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply46
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply46
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?46
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply46
Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?45
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension45
Editorial: Can we predict or not predict response to hypnotherapy? That is the question44
Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—TheMAFLDfibrosis score44
Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis43
First in human randomised trial of J2H‐1702: A novel 11β‐hydroxysteroid dehydrogenase type 1 inhibitor for non‐alcoholic steatohepatitis treatment43
Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply42
Diagnostic Accuracy of an Add‐On, Blood‐Based Screening Test for Colorectal Cancer in Two Established Screening Programmes42
0.10842800140381